ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1163

The Receptor For Advanced Glycation End Products (RAGE) As a Modulator Of Inflammatory Responses and Its Contribution To Gender-Specific Effects During Arthritis

Timo Wirth1, Christoph Kessel1, Philipp Becker2, Toni Weinhage3, Nadine Nippe4 and Dirk Foell5, 1Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, 2University of Muenster, Muenster, Germany, 3Pediatric Rheumatology and Immunology, University of Muenster, Münster, Germany, 4Department of Dermatology, University of Muenster, Münster, Germany, 5Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Inflammation, inflammatory arthritis and innate immunity, Pathophysiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor expressed on various cells which interacts with a diverse class of ligands, e.g. ‘danger signals’ such as neutrophil-derived S100A12. RAGE has been implicated in the pathogenicity of various inflammatory diseases including inflammatory arthritis. However, the exact role of RAGE has not been sufficiently defined. Our recent data on S100A12-induced activation of monocytes points to a modulatory rather than pro-inflammatory function of human RAGE. To assess the role of RAGE in a more systematic way, we generated RAGE-/- mice and analyzed immune cell functions in vitro, followed by murine models of staphylococcus aureus infection (host defense), chemically induced colitis (mucosal immunity), lethal inflammatory liver injury (septic shock) and collagen induced arthritis (autoimmunity) comparing RAGE-/- and C57BL/6 wildtype (wt) mice.

Methods: Reactive oxygen species (ROS) production, phagocytosis and cytokine production of bone marrow derived monocytes were measured using flow cytometry. Staphylococcus aureus (S. aureus)infection was induced by footpad injection. Acute and chronic colitis were induced chemically by dextran sodium sulfate (DSS) solution. For the inflammatory liver injury model, mice were challenged with D-galactosamine (D-Gal) along with lipopolysaccharide (LPS). Arthritis was induced by injection of heterologous type II collagen (CII). 

Results: We observed no differences of cellular immune function (ROS and cytokine production, phagocytosis) in RAGE-/- compared to wt monocytes. Male, but not female RAGE-/- mice showed more footpad swelling and bacterial dissemination in the S. aureus infection model. In the DSS colitis model we observed no significant differences between the two strains, whereas RAGE-/- mice were significantly protected from lethal D‑Gal/LPS induced liver injury. RAGE-/- and wt mice develop arthritis at similar clinical scores and incidence with no significant differences in type II collagen autoantibody levels. However, in female animals there is a strong tendency towards aggravated disease, less remission and higher disease penetrance. 

Conclusion: Overall, the contribution of RAGE seems to largely depend on the disease model and cell type studied. While no overall differences with respect to immune cell activities were observed, a striking gender-specific effect of RAGE seems to be involved in some conditions, especially in arthritis. The exact role of RAGE and its soluble form (sRAGE) during the development of arthritis and the influence of gender-specific factors is under further investigation.


Disclosure:

T. Wirth,
None;

C. Kessel,
None;

P. Becker,
None;

T. Weinhage,
None;

N. Nippe,
None;

D. Foell,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-receptor-for-advanced-glycation-end-products-rage-as-a-modulator-of-inflammatory-responses-and-its-contribution-to-gender-specific-effects-during-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology